RxDoctor Payments Data

Devan Stetson

Physician Assistant · Newport Beach, CANPI 1134855190

Payments from drug & device makers

$659in general payments, 2019–2025

Across 24 payments — averaging $27.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$142
  • Novartis$139
  • Mayne Pharma Commercial LLC$122
  • Novo Nordisk$111
  • Lilly USA, LLC$64
  • Amgen$44
  • plus $38 from 2 others

What the payments were for

  • Food & beverage$659100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$659 in reported general payments places this provider in the 65th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$25,248
Medicare patients
124
Services billed
544

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban16$15,233
EntrestoSacubitril/Valsartan13$12,441
MounjaroTirzepatide12$12,339
SynthroidLevothyroxine Sodium16$1,853
Rosuvastatin Calcium37$883
Testosterone13$730
Insulin SyringeSyring-Needl,disp,insul,0.3 Ml11$457
Atorvastatin Calcium54$407
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine15$338
Levothyroxine Sodium41$292
Tamsulosin Hcl30$281
Zolpidem Tartrate43$278
Duloxetine Hcl19$264
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen14$229
Etodolac16$228

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$139$12,44113 claims
Lilly USA, LLCMounjaro$64$12,33912 claims
AbbVieSynthroid$20$1,85316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Newport Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →